PCJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Solid Gross MarginA 150% TTM revenue rebound to $14.5M combined with a ~52% gross margin indicates the company is converting early commercial activity into higher-quality top-line results. This durable improvement supports scaling commercialization and suggests unit economics that can expand with volume, reducing reliance on non‑recurring gains.
Broad Payer Coverage And Initial Market AccessPublished coverage for 95% of commercially insured lives and no final denials reported imply structurally stronger reimbursement access. Durable payer acceptance lowers reimbursement risk, supports sustained cash collections as volumes grow, and improves predictability for long‑term commercial rollouts across treatment centers.
Manageable Leverage And A Scaled Balance SheetA low debt-to-equity (~0.16) and materially larger asset/equity base versus prior years provide financial flexibility to fund near-term commercialization and selective R&D investments. This balance-sheet strength improves optionality for non-dilutive financing, partnerships, or staged capital deployment as commercial scale builds.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flows (~-$78M and -$85M TTM) indicate the business currently consumes large amounts of capital to run operations. Over a multi-month horizon this reliance on external funding elevates refinancing and dilution risk and constrains the firm's ability to invest without additional capital.
Earnings Quality DisconnectThe divergence of positive reported net income from deeply negative EBIT/EBITDA and cash flows suggests earnings are driven by non‑operating or one‑time items. This weakens confidence that reported profitability is sustainable, complicates forecasting, and raises the risk that future earnings may not translate into free cash generation.
High Operating Expenses And Commercialization Cadence RiskRapid SG&A expansion (Q1 SG&A $19.5M, +$9.7M YoY) increases fixed cost burden during early commercialization. Coupled with variable QTC onboarding times and lengthy insurer approvals, higher operating expenses can prolong the path to sustained profitability and pressure cash runway if patient volumes ramp slower than planned.
Abeona Therapeutics News
PCJ FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is CHF295.55M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on May 13, 2026. The company reported -CHF0.242 earnings per share for the quarter, beating the consensus estimate of -CHF0.271 by CHF0.028.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Abeona Therapeutics have?
Currently, no data Available
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -CHF0.242 in its last earnings report, beating expectations of -CHF0.271. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in CH:PCJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF15.95 (― Upside)
CHF15.95 (― Upside)
Blogger Sentiment
Bullish
CH:PCJ Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth CHF1.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
PCJ Company Deck
PCJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.View all CH:PCJ earnings summaries